Plethora Solutions Holdings Plc Regulatory News (PLE)

3 February 2011

Plethora Solutions Holdings plc

("Plethora" or "the Company")

Trading Update, Board and Senior Management Appointments

Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces a trading update of unaudited information following the completion of the financial year ended 31 December 2010. In addition, the Company can also announce the appointment of Richard Horsman as a non-executive director of the Company and the appointment of Billy Hargan as VP Commercial Operations.

Trading Update

During 2010 Plethora successfully established The Urology Company, its speciality pharmaceutical marketing and distribution subsidiary. The objective is to become a profitable, focussed business in an underserved niche where the Company has significant expertise.

The focus during 2010 was to build the required operational and regulatory infrastructure and generate maiden revenues. The Urology Company launched eleven products during the year, including prescription pharmaceuticals and consumer healthcare products, which was ahead of expectations.

For 2011, the primary goal for The Urology Company is to grow revenues to a material degree so that the business makes a significant financial contribution to the Company's results. This will be achieved through organic sales growth of launched products, the launch of new products and the acquisition new products.

In 2009 Plethora entered into a global licensing agreement with Shionogi Pharma, Inc. ('Shionogi') for PSD502, a development stage treatment for premature ejaculation. Shionogi is now responsible for all activities relating to the regulatory filing and launch of the product. During 2010, the Company received substantial payments from Shionogi for the reimbursement of costs incurred by Plethora in the development of the product and should receive milestone and royalty payments in due course.

The Company anticipates announcing full preliminary results for the year ended 31 December 2010 in March 2011. These results are expected to show total revenues of approximately £1.15 million, broadly in line with market expectations and cash balances in excess of £750,000.

Board & Senior Management Appointments

Plethora also announces two senior appointments. Mr Richard Horsman has been appointed as a non-executive director and Mr Billy Hargan has been appointed as VP Commercial Operations.

Richard Horsman was previously CEO of Cybit Holdings plc. During his tenure at Cybit he grew the company from inception to revenues of £25 million and took the company through multiple acquisitions. In January 2010 Cybit was acquired in a deal with a US based private equity firm which returned £24 million to shareholders at over a 100% premium to the prevailing market price. Prior to this Richard held a number of senior roles in the IT industry including with Global Telematics PLC and The Baan Company. Richard will assume the roles of senior independent non-executive director and chairman of the remuneration committee.

Billy Hargan joins the Company as VP Commercial Operations. Billy will be responsible for leading the sales and marketing effort of The Urology Company. Billy brings a depth of directly relevant commercial experience in the sales and marketing of pharmaceuticals in a specialist environment. Prior to joining Plethora he was General Manager UK at Specialty European Pharma Limited, a business with a focus in urology and uro-oncology. Prior to that Billy was Commercial Operations Director at Hospira Healthcare BV, a speciality pharmaceutical spin-off from Abbott Laboratories. He has also held senior roles with Abbott Laboratories, Knoll AG, Boots Pharmaceuticals and Gist-Brocades.

Bill Robinson, Plethora Chairman, said:

"2010 has seen a period of substantial development towards our goal of becoming a profitable speciality pharmaceutical company. The product launches during the year established a base from which to grow revenues substantially in 2011. In addition, we are delighted to welcome Richard and Billy to Plethora. The commitment of such high calibre individuals underscores the opportunity which we intend to deliver over the coming months."

-Ends-

Enquiries:

AIM Rules disclosure in relation to the appointment of Richard John Horsman (aged 49) as a director of the Company

Current directorships/Partnerships:

JC Mackinlay and Co Limited

High Lees Farms LP

1624 Equine Couture LP

Past Directorships:

Cybit Holdings Plc

Bluefinger Limited

Amatics Limited

There are no other disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Notes to Editors:

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503 - Virgafem), interstitial cystitis (PSD597 - Urolieve) erectile dysfunction (PSD510) and premature ejaculation (PSD502).

Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of branded and generic pharmaceutical products, pharmaceutical specials, medical devices and nutritional supplements for the treatment of urology, andrology and obstetric conditions.

The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk and www.theurologyco.com